Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Summit Therapeutics Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.46, while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MSTZ | SMMT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $29.32 |
52-Week Low | $3.50 | $13.05 |
Market Cap | — | $10.48B |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $11.49, down 6.2% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock faces resistance at $12 and support at $11. Financial ratios remain unavailable, limiting fundamental assessment. Recent news highlights ETF performance trends but provides limited direct company insights.
The outlook remains uncertain due to incomplete financial data and mixed technical indicators. Investment opportunity depends on forthcoming financial disclosures, while risks include market volatility and lack of clear fundamental anchors. Current sentiment appears neutral with limited analyst coverage.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
